Skip to main content
  • Clinical
      |Clinical
    • Acute Coronary Syndromes
    • Cardiac Surgery
    • Covid-19
    • Heart Failure
    • Heart Health
    • Heart Rhythm
    • Hypertension
    • Interventional Cardiology
    • Mitral Valve
    • Pharmaceutics
    • Structural Heart Disease
    • TAVR
    • Tricuspid Valve
    • Vascular & Endovascular
  • Management
      |Management
    • Chest Pain Guidelines
    • Compensation
    • Economics
    • Education & Training
    • Legal News
    • Patient Care
    • Policy & Regulations
    • Professional Associations
    • Quality
    • Revenue
    • Staffing
  • Technology
      |Technology
    • AI
    • Cardiac Imaging
    • Cath Lab
    • CT
    • CVIS
    • ECG
    • Echo
    • EP Lab
    • Informatics
    • MRI
    • Nuclear Cardiology
    • Remote Monitoring
  • Videos
  • Conferences
      |Conferences
    • ACC
    • AHA
    • ASE
    • ASNC
    • ESC
    • EuroPCR
    • HFSA
    • HRS
    • SCAI
    • SCCT
    • SIIM
    • SNMMI
    • STS
    • TCT
    • VIVA
  • Custom Content
      |Custom Content
    • Experience Stories
    • Webinars & Videos
  • Subscribe
  • Forty Under 40 Award
      |Forty Under 40 Award
    • Class of 2026
    • Class of 2025

Search form

Home

News Alert: FDA, FTC warn 10 companies for making ‘fraudulent claims’ about unapproved diabetes supplements

News You Need to Know Today
News Alert: FDA, FTC warn 10 companies for making ‘fraudulent claims’ about unapproved diabetes supplements
Thursday, September 9, 2021
Link to Twitter Link to Facebook Link to Linkedin Link to Vimeo

News Alert

FDA, FTC warn 10 companies for making ‘fraudulent claims’ about unapproved diabetes supplements

Each company is believed to be in violation of the Federal Food, Drug and Cosmetic Act. They have 15 working days to respond. 

READ MORE >
pills-384846_960_720.jpg
Share on Twitter Share on Facebook Share on Linkedin

FDA, FTC warn 10 companies for making ‘fraudulent claims’ about unapproved diabetes supplements

Share on Twitter Share on Facebook Share on Linkedin
pills-384846_960_720.jpg
Each company is believed to be in violation of the Federal Food, Drug and Cosmetic Act. They have 15 working days to respond. 
READ MORE >

Innovate Healthcare thanks our partners for supporting our newsletters.
Sponsorship has no influence on editorial content.

Interested in reaching our audiences, contact our team

*|LIST:ADDRESSLINE|*

You received this email because you signed up for newsletters from Innovate Healthcare.
Change your preferences or unsubscribe here

Contact Us  |  Unsubscribe from all  |  Privacy Policy

© Innovate Healthcare, a TriMed Media brand
Innovate Healthcare

Recent Newsletters

TAVR Highlights: AI alerts make a big impact | When PCI can wait | A key FDA approval | New stroke prevention tech | AKI risks
New tricuspid valve OK for US trial | Drug shows clear long-term cardiac amyloid survival | Faster PFA ablations
FDA clears new software for mitral valve repair | AI-powered CCTA assessments vs. IVUS | Safety in the cath lab
Cardiology practice pays $3.5M in data breach settlement | Key ACC trials | More screening, treatment needed for CKD
Software errors lead to major insulin pump recall | FDA approves another GLP-1 pill | Premature menopause & the heart
Hospital sues cardiology practice | Cardiologist fired for speaking out, lawsuit claims | FDA approves another GLP-1 pill
Week in Review: ‘Practice-changing’ cardiology research | Another Impella recall | FDA clears AI for pulmonary hypertension

Pagination

    • First page « First
    • Previous page ‹‹
    • Page …13
    • Page 14
    • Page 15
    • Page 16
    • Current page 17
    • Page 18
    • Page 19
    • Page 20
    • Page 21 …
    • Next page ››
    • Last page Last »
  • Home
  • News
  • Article Archive
  • Custom Content
  • Webinars
  • Press Releases
  • Content Studio
  • Advertising
  • Submit Press Release
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Cardiovascular Business
  • HealthExec
  • Radiology Business
 
© 2026 Innovate Healthcare | All Rights Reserved. | Terms of Use | Privacy Policy
 
Design by Adaptive Theme